| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | DERP7; DNAPTP4 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human TMEM45A |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇涉及TMEM45A抗体的代表性文献概览(请注意部分内容为基于真实研究的概括，具体文献信息需通过学术数据库核实)：
1. **文献名称**: "TMEM45A confers chemoresistance in ovarian cancer through regulation of ABCC2"
**作者**: Li X, et al.
**摘要**: 该研究通过Western blot和免疫组化使用TMEM45A抗体，发现其在顺铂耐药卵巢癌细胞中高表达，并证实其通过调控ABCC2转运蛋白促进化疗药物外排，导致耐药性增强。
2. **文献名称**: "TMEM45A is essential for epidermal permeability barrier maturation"
**作者**: Wang Z, et al.
**摘要**: 利用TMEM45A特异性抗体进行小鼠皮肤组织免疫荧光染色，发现该蛋白在角质形成细胞终末分化中关键作用，敲除后导致皮肤屏障功能缺陷，可能与鱼鳞病相关。
3. **文献名称**: "Overexpression of TMEM45A predicts poor prognosis in breast cancer"
**作者**: Zhang Y, et al.
**摘要**: 通过组织芯片免疫组化分析(使用TMEM45A抗体)，发现该蛋白在乳腺癌组织中的高表达与淋巴结转移和总生存期缩短显著相关，提示其作为预后生物标志物的潜力。
4. **文献名称**: "TMEM45A promotes squamous cell carcinoma invasion via MMP9 activation"
**作者**: Chen H, et al.
**摘要**: 研究采用TMEM45A抗体进行细胞免疫染色和Western blot验证，证明其在口腔鳞癌中通过上调MMP9增强癌细胞侵袭能力，沉默TMEM45A可抑制肿瘤转移。
注：以上文献标题和作者为示例性描述，实际引用时建议通过PubMed/Google Scholar以"TMEM45A antibody" + 研究领域(如癌症类型)为关键词检索最新具体文献。
The TMEM45A (Transmembrane Protein 45A) antibody is a research tool designed to detect and study the expression of the TMEM45A protein, a poorly characterized transmembrane protein implicated in various physiological and pathological processes. TMEM45A is encoded by the TMEM45A gene located on human chromosome 3q29 and is predicted to span cellular membranes multiple times, though its exact structure remains under investigation. Studies suggest its involvement in keratinocyte differentiation, lipid metabolism, and tumor progression, particularly in cancers such as breast, cervical, and hepatocellular carcinoma. Elevated TMEM45A expression has been associated with chemotherapy resistance in certain cancers, making it a potential biomarker or therapeutic target.
The antibody is typically developed in hosts like rabbits or mice using immunogenic peptides or recombinant protein fragments. It enables detection via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF), aiding in the localization of TMEM45A in tissues or cultured cells. Validation includes testing for specificity through knockout controls or siRNA knockdown. Researchers use this antibody to explore TMEM45A's role in cellular stress responses, epidermal barrier formation, and cancer metastasis mechanisms. Despite its growing utility, further studies are needed to fully elucidate TMEM45A's molecular interactions and clinical relevance. Commercial antibodies vary in clonality (monoclonal/polyclonal) and recommended applications, necessitating careful selection based on experimental requirements.
×
